Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

amivantamab

(A-mih-VAN-tuh-mab)
A drug used alone or with other drugs to treat adults with non-small cell lung cancer that has spread and has an abnormal EGFR gene. It is used in patients whose cancer has not been treated with other anticancer therapy or has gotten worse during or after treatment with an EGFR tyrosine kinase inhibitor (a type of anticancer drug) or platinum chemotherapy. It is also being studied in the treatment of other types of cancer. Amivantamab binds to receptors for proteins called EGF and MET, which are found on some types of cancer cells. Blocking these proteins may help keep cancer cells from growing. Amivantamab is a type of bispecific antibody. Also called Rybrevant.
More Information
Search NCI's Dictionary of Cancer Terms